AI is rapidly redefining bladder cancer management through multimodal data integration and predictive modeling. While current evidence demonstrates high diagnostic and prognostic performance, clinical implementation remains limited by heterogeneity, lack of standardization and insufficient external validation. Future efforts should prioritize prospective validation, explainability and integration into clinical workflows to realize AI's full potential in personalized uro-oncology.
Salzano et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: